[{"address1": "200-3650 Gilmore Way", "city": "Burnaby", "state": "BC", "zip": "V5G 4W8", "country": "Canada", "phone": "604 484 3300", "fax": "604 484 3450", "website": "https://www.xenon-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.", "fullTimeEmployees": 316, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.", "age": 49, "title": "President, CEO, Principal Accounting Officer & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 1184288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea  DiFabio J.D.", "age": 57, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 682252, "exercisedValue": 0, "unexercisedValue": 436894}, {"maxAge": 1, "name": "Dr. Christopher John Kenney M.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 774702, "exercisedValue": 0, "unexercisedValue": 4053263}, {"maxAge": 1, "name": "Mr. Thomas Patrick Kelly J.D.", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew D. Ronsheim Ph.D.", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shelley  McClCoskey B.A.", "age": 65, "title": "Executive Vice President of Human Resources", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robin P. Sherrington Ph.D.", "age": 64, "title": "Executive Vice President of Strategy & Innovation", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 587028, "exercisedValue": 0, "unexercisedValue": 9907717}, {"maxAge": 1, "name": "Dr. James R. Empfield Ph.D.", "age": 64, "title": "Executive Vice President of Drug Discovery", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 323428, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darren S. Cline M.B.A.", "age": 61, "title": "Chief Commercial Officer and Member of Executive Team", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Colleen  Alabiso", "title": "Senior Vice President of Corporate Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 2, "compensationRisk": 8, "shareHolderRightsRisk": 3, "overallRisk": 4, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 40.74, "open": 40.92, "dayLow": 39.97, "dayHigh": 41.24, "regularMarketPreviousClose": 40.74, "regularMarketOpen": 40.92, "regularMarketDayLow": 39.97, "regularMarketDayHigh": 41.24, "payoutRatio": 0.0, "beta": 0.977, "forwardPE": -8.748492, "volume": 975522, "regularMarketVolume": 975522, "averageVolume": 872901, "averageVolume10days": 1240560, "averageDailyVolume10Day": 1240560, "bid": 39.5, "ask": 40.61, "bidSize": 13, "askSize": 13, "marketCap": 3089454848, "fiftyTwoWeekLow": 26.74, "fiftyTwoWeekHigh": 46.6, "allTimeHigh": 50.99, "allTimeLow": 2.1, "priceToSalesTrailing12Months": 411.9273, "fiftyDayAverage": 42.3874, "twoHundredDayAverage": 36.95225, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2635513600, "profitMargins": 0.0, "floatShares": 71790025, "sharesOutstanding": 77275005, "sharesShort": 5927441, "sharesShortPriorMonth": 5889334, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0767, "heldPercentInsiders": 0.0011, "heldPercentInstitutions": 1.13131, "shortRatio": 7.68, "shortPercentOfFloat": 0.0855, "impliedSharesOutstanding": 77275005, "bookValue": 7.255, "priceToBook": 5.510682, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -306334016, "trailingEps": -3.89, "forwardEps": -4.56993, "enterpriseToRevenue": 351.402, "enterpriseToEbitda": -7.793, "52WeekChange": 0.025654197, "SandP52WeekChange": 0.14725316, "quoteType": "EQUITY", "currentPrice": 39.98, "targetHighPrice": 65.0, "targetLowPrice": 44.0, "targetMeanPrice": 55.50737, "targetMedianPrice": 55.0, "recommendationMean": 1.15, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 19, "totalCash": 462268000, "totalCashPerShare": 5.982, "ebitda": -338182016, "totalDebt": 8327000, "quickRatio": 12.08, "currentRatio": 12.525, "totalRevenue": 7500000, "debtToEquity": 1.488, "revenuePerShare": 0.095, "returnOnAssets": -0.29505, "returnOnEquity": -0.45138, "grossProfits": -265211008, "freeCashflow": -162175504, "operatingCashflow": -252022000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -45.43733, "financialCurrency": "USD", "symbol": "XENE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Xenon Pharmaceuticals Inc.", "longName": "Xenon Pharmaceuticals Inc.", "twoHundredDayAverageChange": 3.027748, "twoHundredDayAverageChangePercent": 0.08193677, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1768602310, "regularMarketTime": 1768597201, "exchange": "NGM", "messageBoardId": "finmb_565718", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -1.86549, "regularMarketPrice": 39.98, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1415197800000, "postMarketChangePercent": 1.150573, "postMarketPrice": 40.44, "postMarketChange": 0.45999908, "regularMarketChange": -0.760002, "regularMarketDayRange": "39.97 - 41.24", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 872901, "fiftyTwoWeekLowChange": 13.24, "fiftyTwoWeekLowChangePercent": 0.49513838, "fiftyTwoWeekRange": "26.74 - 46.6", "fiftyTwoWeekHighChange": -6.619999, "fiftyTwoWeekHighChangePercent": -0.14206007, "fiftyTwoWeekChangePercent": 2.5654197, "earningsTimestamp": 1762203600, "earningsTimestampStart": 1762203600, "earningsTimestampEnd": 1762203600, "earningsCallTimestampStart": 1762205400, "earningsCallTimestampEnd": 1762205400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.89, "epsForward": -4.56993, "epsCurrentYear": -4.26927, "priceEpsCurrentYear": -9.364598, "fiftyDayAverageChange": -2.407402, "fiftyDayAverageChangePercent": -0.056795225, "displayName": "Xenon Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]